Loading
A phase 2 trial of balstilimab and botensilimab in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma is a phase 2, interventional study registered as NCT06843434 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 40 participants, started 2025-02-20 and due to reach its primary completion in 2028-02-20. Interventions recorded: Balstilimab; Botensilimab. Conditions listed: Microsatellite Stable Rectal Carcinoma; Locally Advanced Rectal Adenocarcinoma. Primary outcome: Best Overall Response Rate. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Agenus, Botensilimab, Balstilimab, Mismatch-repair deficient (MSI-high) colorectal cancer and the tag colorectal-deep-dive.
Shares Agenus, Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Agenus, Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer, Immune checkpoint inhibitors and the tag colorectal-deep-dive.